


Medicure inks agreement with Reliance LS for marketing cardiovascular biosimilar

06 October 2020 | News

The Agreement grants an exclusive right to Medicure to market and sell the Product in the United States of America, Canada and the European Union.



Medicure Inc., a pharmaceutical company based in the US, has announced that through its wholly-owned subsidiary, Medicure International Inc., it has entered into a License, Manufacture and Supply Agreement with Reliance Life Sciences for a cardiovascular biosimilar.

Medicure is responsible for the regulatory approval process for the product. A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an approved reference product.

The Agreement grants an exclusive right to Medicure to market and sell the Product in the United States of America, Canada and the European Union.

"We are very pleased with the agreement we have reached with RLS. The Product fits well with Medicure's mission of being a significant cardiovascular company focused on the U.S. market." commented Dr. Albert Friesen, Chief Executive Officer for Medicure. "We look forward to the growth of our portfolio of cardiovascular products."